Long non-coding RNA TUC338 is functionally involved in sorafenib-sensitized hepatocarcinoma cells by targeting RASAL1

Jin,Weidong; Chen,Lei; Cai,Xun; Zhang,Yunxiao; Zhang,Jianxin; Ma,Dangdang; Cai,Xiong; Fu,Tao; Yu,Zhengping; Yu,Fuxiang; Chen,Gang

doi:10.3892/or.2016.5248

Long non-coding RNA TUC338 is functionally involved in sorafenib-sensitized hepatocarcinoma cells by targeting RASAL1

Authors:
- Weidong Jin
- Lei Chen
- Xun Cai
- Yunxiao Zhang
- Jianxin Zhang
- Dangdang Ma
- Xiong Cai
- Tao Fu
- Zhengping Yu
- Fuxiang Yu
- Gang Chen
View Affiliations

Affiliations: Department of General Surgery, Wuhan General Hospital of Guangzhou Military, Wuhan, Hubei 430000, P.R. China, Department of Hepatobiliary Surgery, Wenzhou Central Hospital, Wenzhou, Zhejiang 325000, P.R. China, Renji College of Wenzhou Medical University, Wenzhou, Zhejiang 325000, P.R. China, Department of Hepatobiliary Surgery, The First Affiliated Hospital, Wenzhou Medical University, Wenzhou, Zhejiang 325000, P.R. China
Published online on: November 15, 2016 https://doi.org/10.3892/or.2016.5248
Pages: 273-280

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Development of novel targeted therapy holds promise for conquering chemotherapy resistance, one of major hurdles in current liver cancer treatment. We found that long non-coding RNA TUC338 is involved in the development of hepatocellular carcinoma (HCC) and sorafenib resistance. HCC cell lines were transfected with siTUC338, then cell proliferation and invasion ability were investigated by MTT and Transwell assay. Sorafenib resistance HepG2 cells were generated to test the role of TUC338 in sorafenib sensitivity. Intratumoral delivering of siTUC338 was used to analyze the sorafenib treatment response in HepG2/Sor xenografts in vivo. Higher levels of TUC338 were found both in HCC tissues and cell lines, knockdown of TUC338 was accompanied with increased expression of RASAL1 in HCC cell line with increased proliferation and invasion ability, knockdown of TUC338 could activate the RASAL1 pathway and inhibit tumor growth genes by directly targeting RASAL1 3'-UTR. Furthermore, knockdown of TUC338 in HepG2 sorafenib sensitized its reaction to the treatment of sorafenib, which was accompanied by increased expression RASAL1; intratumoral delivering of siTUC338 could also restore sorafenib treatment response in HepG2/Sor xenografts in vivo. These findings provide direct evidence that the TUC338/RASAL1 axis might play an essential role in sorafenib-resistance of liver cancer cells, suggesting the signaling cohort could serve as a novel therapeutic target for the treatment of chemotherapy resistant liver cancer.

View Figures

View References

1	Hernandez-Gea V, Toffanin S, Friedman SL and Llovet JM: Role of the microenvironment in the pathogenesis and treatment of hepatocellular carcinoma. Gastroenterology. 144:512–527. 2013. View Article : Google Scholar : PubMed/NCBI
2	de Lope CR, Tremosini S, Forner A, Reig M and Bruix J: Management of HCC. J Hepatol. 56:(Suppl 1). S75–S87. 2012. View Article : Google Scholar : PubMed/NCBI
3	Spinzi G and Paggi S: Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 359:2497–2498. 2008. View Article : Google Scholar : PubMed/NCBI
4	Glackin CA: Targeting the Twist and Wnt signaling pathways in metastatic breast cancer. Maturitas. 79:48–51. 2014. View Article : Google Scholar : PubMed/NCBI
5	Noguchi K, Katayama K and Sugimoto Y: Human ABC transporter ABCG2/BCRP expression in chemoresistance: Basic and clinical perspectives for molecular cancer therapeutics. Pharm Genomics Pers Med. 7:53–64. 2014.
6	Parasramka MA, Maji S, Matsuda A, Yan IK and Patel T: Long non-coding RNAs as novel targets for therapy in hepatocellular carcinoma. Pharmacol Ther. 161:67–78. 2016. View Article : Google Scholar : PubMed/NCBI
7	Birney E, Stamatoyannopoulos JA, Dutta A, Guigó R, Gingeras TR, Margulies EH, Weng Z, Snyder M, Dermitzakis ET, Thurman RE, et al: Children's Hospital Oakland Research Institute: Identification and analysis of functional elements in 1% of the human genome by the ENCODE pilot project. Nature. 447:799–816. 2007. View Article : Google Scholar : PubMed/NCBI
8	Mercer TR, Dinger ME and Mattick JS: Long non-coding RNAs: Insights into functions. Nat Rev Genet. 10:155–159. 2009. View Article : Google Scholar : PubMed/NCBI
9	Derrien T, Johnson R, Bussotti G, Tanzer A, Djebali S, Tilgner H, Guernec G, Martin D, Merkel A, Knowles DG, et al: The GENCODE v7 catalog of human long noncoding RNAs: Analysis of their gene structure, evolution, and expression. Genome Res. 22:1775–1789. 2012. View Article : Google Scholar : PubMed/NCBI
10	Prensner JR and Chinnaiyan AM: The emergence of lncRNAs in cancer biology. Cancer Discov. 1:391–407. 2011. View Article : Google Scholar : PubMed/NCBI
11	Braconi C, Valeri N, Kogure T, Gasparini P, Huang N, Nuovo GJ, Terracciano L, Croce CM and Patel T: Expression and functional role of a transcribed noncoding RNA with an ultraconserved element in hepatocellular carcinoma. Proc Natl Acad Sci USA. 108:786–791. 2011. View Article : Google Scholar : PubMed/NCBI
12	Braconi C and Patel T: Non-coding RNAs as therapeutic targets in hepatocellular cancer. Curr Cancer Drug Targets. 12:1073–1080. 2012. View Article : Google Scholar : PubMed/NCBI
13	George J and Patel T: Noncoding RNA as therapeutic targets for hepatocellular carcinoma. Semin Liver Dis. 35:63–74. 2015. View Article : Google Scholar : PubMed/NCBI
14	Liu D, Yang C, Bojdani E, Murugan AK and Xing M: Identification of RASAL1 as a major tumor suppressor gene in thyroid cancer. J Natl Cancer Inst. 105:1617–1627. 2013. View Article : Google Scholar : PubMed/NCBI
15	Ohta M, Seto M, Ijichi H, Miyabayashi K, Kudo Y, Mohri D, Asaoka Y, Tada M, Tanaka Y, Ikenoue T, et al: Decreased expression of the RAS-GTPase activating protein RASAL1 is associated with colorectal tumor progression. Gastroenterology. 136:206–216. 2009. View Article : Google Scholar : PubMed/NCBI
16	Ngeow J and Eng C: RASAL1 in thyroid cancer: Wisdom from an old foe. J Natl Cancer Inst. 105:1597–1599. 2013. View Article : Google Scholar : PubMed/NCBI
17	Chen H, Cheng Z-Y, Pan Y, Wang Z, Liu Y and Zhang J-Q: RASAL1 influences the proliferation and invasion of gastric cancer cells by regulating the RAS/ERK signaling pathway. Hum Cell. 27:103–110. 2014. View Article : Google Scholar : PubMed/NCBI
18	Kolfschoten IG, van Leeuwen B, Berns K, Mullenders J, Beijersbergen RL, Bernards R, Voorhoeve PM and Agami R: A genetic screen identifies PITX1 as a suppressor of RAS activity and tumorigenicity. Cell. 121:849–858. 2005. View Article : Google Scholar : PubMed/NCBI
19	Walker SA, Kupzig S, Bouyoucef D, Davies LC, Tsuboi T, Bivona TG, Cozier GE, Lockyer PJ, Buckler A, Rutter GA, et al: Identification of a Ras GTPase-activating protein regulated by receptor-mediated Ca²⁺ oscillations. EMBO J. 23:1749–1760. 2004. View Article : Google Scholar : PubMed/NCBI
20	Loriot Y, Mordant P, Deutsch E, Olaussen KA and Soria J-C: Are RAS mutations predictive markers of resistance to standard chemotherapy? Nat Rev Clin Oncol. 6:528–534. 2009. View Article : Google Scholar : PubMed/NCBI
21	Li W, Zhai B, Zhi H, Li Y, Jia L, Ding C, Zhang B and You W: Association of ABCB1, β tubulin I, and III with multidrug resistance of MCF7/DOC subline from breast cancer cell line MCF7. Tumour Biol. 35:8883–8891. 2014. View Article : Google Scholar : PubMed/NCBI
22	Febriansah R, Putri DD, Sarmoko Nurulita NA, Meiyanto E and Nugroho AE: Hesperidin as a preventive resistance agent in MCF-7 breast cancer cells line resistance to doxorubicin. Asian Pac J Trop Biomed. 4:228–233. 2014. View Article : Google Scholar : PubMed/NCBI
23	Tomayko MM and Reynolds CP: Determination of subcutaneous tumor size in athymic (nude) mice. Cancer Chemother Pharmacol. 24:148–154. 1989. View Article : Google Scholar : PubMed/NCBI
24	Qiao F, Su X, Qiu X, Qian D, Peng X, Chen H, Zhao Z and Fan H: Enforced expression of RASAL1 suppresses cell proliferation and the transformation ability of gastric cancer cells. Oncol Rep. 28:1475–1481. 2012.PubMed/NCBI
25	Villanueva A and Llovet JM: Second-line therapies in hepatocellular carcinoma: Emergence of resistance to sorafenib. Clin Cancer Res. 18:1824–1826. 2012. View Article : Google Scholar : PubMed/NCBI
26	Zhai B and Sun X-Y: Mechanisms of resistance to sorafenib and the corresponding strategies in hepatocellular carcinoma. World J Hepatol. 5:345–352. 2013. View Article : Google Scholar : PubMed/NCBI
27	Yu W, Qiao Y, Tang X, Ma L, Wang Y, Zhang X, Weng W, Pan Q, Yu Y, Sun F, et al: Tumor suppressor long non-coding RNA, MT1DP is negatively regulated by YAP and Runx2 to inhibit FoxA1 in liver cancer cells. Cell Signal. 26:2961–2968. 2014. View Article : Google Scholar : PubMed/NCBI